A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Secukinumab (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- Acronyms ORBIT
- Sponsors Novartis Pharmaceuticals
- 10 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2023 This trial has been competed in Germany (End Date: 16 May 2023), according to European Clinical Trials Database record.
- 16 Mar 2023 Planned End Date changed from 5 Feb 2025 to 1 Feb 2027.